然而癌前病变是已经公认的肠化生还是更难于探及的不典型增生。
Yet is the premalignant lesion the readily recognized intestinal metaplasia or the more difficult to detect dysplasia?
公认的肠化生或更难发现的异型增生是否做为癌前病变得到检测？
Is the premalignant lesion to be detected the readily recognized intestinal metaplasia or the more difficult to detect dysplasia?
结论：p 53蛋白可在胃癌的早期诊断中起作用，其改变在胃癌发生的早期即居于肠化生阶段的癌前变化过程中。
Conclusion: P53 protein can be used in early clinical diagnosis. Early in gastric carcinogenesis, its change occurs at intestinal metaplasia stage.
该问题是评估低流行癌前病变(如，胃肠化生中的非典型增生)。
The problem is the low prevalence of the premalignant lesion being assessed (ie, dysplasia in gastric intestinal metaplasia).
该问题是评估低流行癌前病变(如，胃肠化生中的非典型增生)。
The problem is the low prevalence of the premalignant lesion being assessed (ie, dysplasia in gastric intestinal metaplasia).
应用推荐